Germany’s Boehringer Ingelheim has made a move to expand its cancer pipeline via a takeover of T3 Pharma, a spinout from the University of Basel in Switzerland. The pharma group is paying CHF 450 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback